Citadel Advisors’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-9,900
| Closed | -$17.3K | – | 14664 |
|
|
2025
Q1 | $17.3K | Buy |
+9,900
| New | +$13.1K | ﹤0.01% | 13244 |
|
|
2024
Q4 | – | Sell |
-29,200
| Closed | -$45.8K | – | 15242 |
|
|
2024
Q3 | $45.8K | Buy |
29,200
+12,200
| +72% | +$20.2K | ﹤0.01% | 12012 |
|
|
2024
Q2 | $30.3K | Sell |
17,000
-9,200
| -35% | -$21.4K | ﹤0.01% | 12261 |
|
|
2024
Q1 | $75.5K | Buy |
26,200
+11,780
| +82% | +$19.2K | ﹤0.01% | 11726 |
|
|
2023
Q4 | $18.5K | Sell |
14,420
-3,200
| -18% | -$4.26K | ﹤0.01% | 12687 |
|
|
2023
Q3 | $24.3K | Sell |
17,620
-3,600
| -17% | -$5.22K | ﹤0.01% | 12464 |
|
|
2023
Q2 | $31.2K | Buy |
21,220
+8,300
| +64% | +$11.1K | ﹤0.01% | 12308 |
|
|
2023
Q1 | $10.9K | Sell |
12,920
-7,200
| -36% | -$9.52K | ﹤0.01% | 13495 |
|
|
2022
Q4 | $27.6K | Sell |
20,120
-310
| -2% | -$487 | ﹤0.01% | 12831 |
|
|
2022
Q3 | $35K | Buy |
+20,430
| New | +$36.8K | ﹤0.01% | 11827 |
|
|
2022
Q2 | – | Sell |
-1,650
| Closed | -$5K | – | 13910 |
|
|
2022
Q1 | $5K | Buy |
1,650
+100
| +6% | +$260 | ﹤0.01% | 13426 |
|
|
2021
Q4 | $5K | Sell |
1,550
-3,350
| -68% | -$14.9K | ﹤0.01% | 13688 |
|
|
2021
Q3 | $34K | Sell |
4,900
-2,690
| -35% | -$19.7K | ﹤0.01% | 13529 |
|
|
2021
Q2 | $62K | Buy |
7,590
+930
| +14% | +$10.4K | ﹤0.01% | 13233 |
|
|
2021
Q1 | $104K | Buy |
+6,660
| New | +$98.6K | ﹤0.01% | 12440 |
|
|
2016
Q2 | – | Sell |
-88
| Closed | -$73K | – | 7301 |
|
|
2016
Q1 | $73K | Buy |
88
+40
| +83% | +$31.8K | ﹤0.01% | 6151 |
|
|
2015
Q4 | $50K | Sell |
48
-14
| -23% | -$14K | ﹤0.01% | 7318 |
|
|
2015
Q3 | $48K | Buy |
62
+41
| +195% | +$42.1K | ﹤0.01% | 7611 |
|
|
2015
Q2 | $27K | Buy |
21
+1
| +5% | +$1.61K | ﹤0.01% | 8020 |
|
|
2015
Q1 | $41K | Sell |
20
-52
| -72% | -$113K | ﹤0.01% | 7510 |
|
|
2014
Q4 | $138K | Buy |
+72
| New | +$128K | ﹤0.01% | 6362 |
|
Other funds holding RGLS
Citadel Advisors's RGLS Position: Q2 2025 in Review
Citadel Advisors sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 148,280 shares — an estimated $259K sold.
Citadel Advisors first reported a position in RGLS in Q4 2014 and held it in 24 quarters. The position peaked at $776K in Q1 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Citadel Advisors reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 148,280 Regulus Therapeutics shares in Q2 2025, an estimated $259K.
- Citadel Advisors first reported a position in Regulus Therapeutics in Q4 2014 and held it in 24 quarters.
- Citadel Advisors's Regulus Therapeutics position peaked at $776K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.